M. Wach

发表

The outcomes of ponatinib therapy in patients with chronic myeloid leukemia resistant or intolerant to previous tyrosine kinase inhibitors, treated in Poland within the donation program

O. Grzybowska-Izydorczyk, J. Góra‐Tybor, E. Patkowska, 2021, Clinical Lymphoma Myeloma and Leukemia.

T Treatment of multiple myeloma patients with reatment of multiple myeloma patients with reatment of multiple myeloma patients with reatment of multiple myeloma patients with reatment of multiple myeloma patients with autologous stem cell transplantation

M. Malek, A. Dmoszyńska, E. Wąsik-Szczepanek, 2011 .

Treatment of multiple myeloma patients with autologous stem cell transplantation - a fresh analysis.

M. Malek, A. Dmoszyńska, W. Legieć, 2011, Folia Histochemica et Cytobiologica.

Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study.

W. Jędrzejczak, K. Sułek, T. Robak, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial.

Jeffrey A Jones, I. Flinn, F. Awan, 2017, The Lancet. Haematology.

Neutropenic enterocolitis: a serious complication during the treatment of acute leukemias

A. Dmoszyńska, D. Szczepanek, A. Drop, 2004, Annals of Hematology.

A multicenter, open, noncomparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, granulocyte colony-stimulating factor and mitoxantrone as induction therapy in refractory acute myeloid leukemia: a report of the Polish Adult Leukemia Group

T. Robak, K. Kuliczkowski, A. Dmoszyńska, 2005, Annals of Hematology.

D. Szczepanek, E. Wąsik-Szczepanek, M. Hus, 2017 .

Autologous Hematopoietic Stem Cell Transplantation for Adults With Acute Myeloid Leukemia.

M. Hus, M. Cioch, J. Mańko, 2016, Transplantation proceedings.

High-dose chemotherapy with autologous stem cell transplantation is an effective treatment of primary refractory Hodgkin's disease. Retrospective study of the Polish Lymphoma Research Group

K. Sułek, R. Dziadziuszko, A. Nagler, 2002, Bone Marrow Transplantation.

Acalabrutinib Versus Investigator’s Choice in Relapsed/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial Results

Á. Illés, M. Šimkovič, P. Ghia, 2022, HemaSphere.

Idelalisib addition has neutral to beneficial effects on quality of life in bendamustine/rituximab-treated patients: results of a phase 3, randomized, controlled trial

A. Zelenetz, J. Delgado, A. Schuh, 2019, Health and Quality of Life Outcomes.

Central nervous involvement by chronic lymphocytic leukaemia.

E. Grywalska, D. Szczepanek, M. Podhorecka, 2017, Neurologia i neurochirurgia polska.

Intravascular B-cell lymphoma in a 38-year-old woman: a case report

J. Szumiło, A. Dmoszyńska, E. Wąsik-Szczepanek, 2001, Annals of Hematology.

Concomitance of monosomal karyotype with at least 5 chromosomal abnormalities is associated with dismal treatment outcome of AML patients with complex karyotype – retrospective analysis of Polish Adult Leukemia Group (PALG)

M. Czyżewska, T. Robak, A. Wierzbowska, 2017, Leukemia & lymphoma.

Addition of cladribine to induction/consolidation regimen does not impair peripheral blood stem cell mobilization and bone marrow harvest for autotransplantation in acute myeloid leukemia patients.

W. Jędrzejczak, A. Skotnicki, A. Wrzesień-kuś, 2005, Transplantation proceedings.

Three-Year Follow-up of the Ascend Trial: Acalabrutinib Vs Rituximab Plus Idelalisib or Bendamustine in Relapsed/Refractory Chronic Lymphocytic Leukemia

J. H. Lee, Á. Illés, M. Šimkovič, 2021, Blood.

ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.

Á. Illés, M. Šimkovič, C. Quah, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Results of a phase III randomized, controlled study evaluating the efficacy and safety of idelalisib (IDELA) in combination with ofatumumab (OFA) for previously treated chronic lymphocytic leukemia (CLL).

Jeffrey A Jones, I. Flinn, Jennifer R. Brown, 2015 .

Attempted reconstruction of the immune system using low doses of interleukin 2 in chronic lymphocytic leukemia patients treated with 2-chlorodeoxyadenosine: results of a pilot study.

A. Dmoszyńska, W. Legieć, M. Wach, 1999, Leukemia & lymphoma.

RESULTS OF A PHASE 3 RANDOMIZED CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF IDELALISIB (IDELA) IN COMBINATION WITH OFATUMUMAB (OFA) FOR PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

Jeffrey A Jones, F. Bosch, P. Feugier, 2015 .

Outcome and prognostic factors in advanced Hodgkin's disease treated with high-dose chemotherapy and autologous stem cell transplantation: a study of 341 patients.

K. Sułek, R. Dziadziuszko, A. Nagler, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Different prognosis of acute myeloid leukemia harboring monosomal karyotype with total or partial monosomies determined by FISH: retrospective PALG study.

T. Robak, A. Wierzbowska, O. Haus, 2013, Leukemia research.

M. Hus, P. Jarosz, M. Cioch, 2014, Transplantation proceedings.

Advances in hematology – research that revolutionized patient care

I. Hus, M. Podhorecka, E. Wąsik-Szczepanek, 2015 .

Acalabrutinib vs Rituximab Plus Idelalisib (IdR) or Bendamustine (BR) by Investigator Choice in Relapsed/Refractory (RR) Chronic Lymphocytic Leukemia: Phase 3 ASCEND Study

Á. Illés, M. Šimkovič, P. Ghia, 2019, Hematological Oncology.

Rb1 gene expression in B-cell lymphocytic leukaemia cases with deletion in the 13q14 region.

M. Antosz, S. Rudzki, J. Wojcierowski, 1997, Cytobios.